Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment?

ISSN: 2165-7890

Autism-Open Access

  • Commentary   
  • Autism Open Access, Vol 7(5)
  • DOI: 10.4172/2165-7890.1000219

Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment?

Hüseyin Sancar Bozkurt1* and Banu Kara2
1Medical Park Private Tarsus Hospital, Clinic of Gastroenterology, Mersin, Turkey
2University of Health Sciences, Adana Numune Research and Education Hospital, Clinic of Gastroenterology, Adana, Turkey
*Corresponding Author: Hüseyin Sancar Bozkurt, Medical Park Private Tarsus Hospital, Gastroenterology, Mersin, Turkey, Tel: 00905054482291, Email: [email protected]

Received Date: Oct 05, 2017 / Accepted Date: Dec 08, 2017 / Published Date: Dec 25, 2017

Abstract

Gastrointestinal microbiota includes bacteria, archaea, viruses, fungi and other eukaryotes. The genus Bifidobacterium is considered the dominant once; it has an important role on immunologic, hormonal and metabolic homeostasis of the host. Recent studies demonstrated that the Mycosporin-like Amino Acids (MAAs) had prebiotic effects and they modulated host immunity by regulating the proliferation and differentiation of intestinal epithelial cells, macrophage and lymphocytes. Also MAAs modulate NF-κB and tryptophan metabolism. Modulation NF-κB and tryptophan metabolism induced a beneficial effect on central nervous cascade. The safety of Bifidobacterium species is known; although they do not produce MAAs, their presence is required for immunological response continuity of intestine. Thereby we hypothesize that if we could create Bifidobacteria species producing MAAs via genetic engineering; they might have stronger immuno-stimulatory properties and might be used as more potent pharmacological agents in neurological diseases secondary to impaired microbiota.

Keywords: Mycosporin-like amino acids; Bifidobacteria; Neurological diseases

Introduction

Microbial organisms live in close association with each other at human’s body. The gut microbiota contains many different ecological community of commensal, symbiotic and pathogenic microorganisms [1,2]. The gut microbiota has anti-inflammatory, antioxidant, antioncogenic effects and it contribute to the immunological, hormonal and metabolic homeostasis of the host [3,4]. The genus Bifidobacterium belonging to Actinobacteria phylum and it consist of Gram-positive, non-motile, often branched anaerobic bacteria [5]. The Bifidobacteria are one of the major species of human colon microbiota and they are frequently used as probiotic agents [6]. Bifidobacterium species have immune modulatory, metabolic and anti-inflammatory effects which are not seen ın other gastro intestinal flora species [5,7-8]. Bifidobacterium species have the highest level of intrinsic hydrogen peroxide resistance causing antioxidant activity. Bifidobacterium’s oligosaccharides metabolism has been shown in many studies; it is separated from others by its fermentation ability [5,9]. Bifidobacteria use the fructose-6-phosphate phosphoketolase pathway to ferment carbohydrates; by this pathway ındigestible fructans turn into Short Chain Fatty Acids (SCFA) as butyrate, which have beneficial effect on intestinal immunity and metabolism [10]. Bifidobacteria are the main source of butyric acid production and they are used as probiotic ingredient in many foods [11,12]. Recently diminished production of SCFAs is considered as the cause of antibiotic-associated diarrhoea, inflammatory bowel disease and neurological disorders [13].

Mycosporin-like amino acids

MAAs are low molecular weight (14]. MAAs acts as UV-absorbers and photoprotectants [14-16]. They improve the growth of beneficial bacteria in the environment of harmful microbiota. MAAs is unique components of red seaweeds and seaweed components are known as supportive reinforcement of the microbiota in intestinal diseases [17-20]. MAAs had been shown to regulate intestinal epithelial cell differentiation and cytokine (IL-1β, IL-6) production [21]. Increased cytokine production, NF-κB activation induced a proliferative effect on epithelial intestinal cells and protect them in experimental colitis secondary to dextran sulphate sodium [22-26]. In vivo experiments showed antiinflammatory effect of MAAs, indicating that they can reinforce membrane barrier function [27-28]. There are two biosynthesis pathways of MAAs. First MAAs biosynthesis pathway is the Shikimate pathway [29] which is known as the synthesis way of aromatic amino acids. Second MAAs biosynthesis pathway is pentose phosphate pathway [30]. In both pathways, 4-deoxygadusol is the common precursor used to produce all MAAs. Trans-aldolase is an enzyme of the non-oxidative phase of the pentose phosphate pathway and Bifidobacterium strains have transaldolase enzyme. Confirmation of a biosynthetic gene cluster for MAAs from Gram-positive bacteria has been showed [31]. Anabaena variabilist PCC 7937 (Cyanobacterium) is able to synthesize MAAs [32]. Genome studies identified a combination of genes, YP_324358 (predicted DHQ synthase) and YP_324357 (O-methyl transferase), which were present only in A. variabilis PCC 7937 and missing in the other Cyanobacteria Anabaena sp. PCC 7120 started to produce MAAs after genomic transfer (YP_324358 and YP_324357 genes) from Anabaena variabilis PCC 7937 [32]. The Bifidobacterium animalis subsp. lactis KLDS 2.0603 strain was demonstrated to have the highest survival rate and adhesion ability in simulated gastrointestinal tract treatments [33]. The comparative genome analysis revealed that the KLDS 2.0603 has most similar whole genome sequence compared with BB-12 strain. It seems that Cyanobacterium is the source of MAAs and we hypothesize that the genes of Cyanobacterium involved in MAAs biosynthesis could be transferred to the strain Bifidobacterium animalis subsp. lactis BB-12.

Bifidobacteria’s role in gut microbiata and neurological system

The human intestinal microbiota influence neuro development, modulate behavior and contribute to neurological disorders. A functional link between gut microbiota and neurological diseases remains unexplored. Sampson et al. showed that gut bacteria regulate movement disorders in mice and suggest that alterations in the human microbiome represent a risk factor for Parkinson Disease (PD) [34]. Also they showed SCFAs modulate microglia and enhance PD pathophysiology. An increase in inflammatory cytokines has been reported previously in autism spectrum disorders and increased cytokines have been reported in association with a regressive autism phenotype with significant communication challenges and aberrant behaviours [34]. Luna et al. have showed distinctive mucosal microbial signatures in children with autism spectrum disorder and functional gastrointestinal disorders that correlated with cytokine, SCFA s and tryptophan homeostasis [35]. Bifidobacterium species provide a lot SCFA as butyrate which has beneficial effect on immunity, metabolism and oncogenesis.

MAAs and gut-brain axis

In central nervous system, NF-κB signaling is as a pro-inflammatory pathway, as it regulates pro-inflammatory cytokine production, leukocyte recruitment, which are important contributors of the inflammatory response. However, the activation of NF-κB signaling in response to stress can also be a strategy of cytoprotection, as several survival pathways can be activated [25]. NF-κB has apoptotic and antiapoptotic properties in central nervous system. Tryptophan is an essential amino acid for neurotransmitter serotonin (5- hydroxytryptamine, 5-HT) products. Impaired tryptophan metabolism has been implicated in the pathophysiology of conditions such as acquired immunodeficiency syndrome-related dementia, Huntington's disease and Alzheimer's disease [36]. The effect of MAAs on central signalling cascades has been investigated in human myelo monocytic THP-1 and THP-1-Blue cells [25]. İt seems that modulation of NF-κB and tryptophan metabolism via MAAs has a beneficial effect on central nervous cascade. Beside these properties MAAs also inhibit thiobarbituric acid reactive oxygen species [37].

Conclusion

Significant progress has been made over the last years in recognizing the importance of gut microbiota to brain function. Key findings show that several neurobiological mechanisms link with gut microbiome alterations that potentially contribute to neurological dysfunction, including reduced SCFA production, neuroinflammation. Creating Bifidobacteria species producing MAAs via genetic engineering could make better quality microbiota and more helpful to human health. MAAs produced via genetic engineering can be used not only as a probiotic, also as a pharmacological agent in intestinal and neurological disorders.

References

Citation: Bozkurt HS, Kara B (2017) Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Diseases’ Treatment?. Autism-Open Access 7: 219. Doi: 10.4172/2165-7890.1000219

Copyright: © 2017 Bozkurt HS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
Article Usage
  • Total views: 833
  • [From(publication date): 0-2017 - Aug 20, 2018]
  • Breakdown by view type
  • HTML page views: 785
  • PDF downloads: 48

Post your comment

captcha   Reload  Can't read the image? click here to refresh
Leave Your Message 24x7